Lucas Moreno Martín-Retortillo I am a doctor specialized in paediatric cancer. I lead the Paediatric Oncology and Haematology Division of Vall d’Hebrón since 2019, with an outstanding team dedicated to providing the best care to our patients and families, and being national and international reference for numerous paediatric cancers. My goal is to improve cancer treatment so that no children and adolescents die of cancer, and that survivors can live a full life free of sequels Instituciones de las que forman parte Jefe de grupo Cáncer y Enfermedades Hematológicas Infantiles Vall Hebron Institut de Recerca Director clínico Oncología y Hematología Pediátrica Hospital Infantil i Hospital de la Mujer LinkedIn Email Lucas Moreno Martín-Retortillo LinkedIn Email Instituciones de las que forman parte Jefe de grupo Cáncer y Enfermedades Hematológicas Infantiles Vall Hebron Institut de Recerca Director clínico Oncología y Hematología Pediátrica Hospital Infantil i Hospital de la Mujer I am a doctor specialized in paediatric cancer. I lead the Paediatric Oncology and Haematology Division of Vall d’Hebrón since 2019, with an outstanding team dedicated to providing the best care to our patients and families, and being national and international reference for numerous paediatric cancers. My goal is to improve cancer treatment so that no children and adolescents die of cancer, and that survivors can live a full life free of sequels
Dr. Lucas Moreno just moved to Barcelona to lead the Paediatric Oncology & Haematology Division at Vall d'Hebron Hospital. He has devoted his career to childhood cancer drug development. His main research interest is in neuroblastoma, one of the most aggressive forms of childhood cancer. After returning from London where he worked at the Royal Marsden Hospital from 2008 to 2012, he created and led the Clinical Trials Unit at Hospital Niño Jesús (Madrid) that became a leading trials unit for paediatric drug development nationally and internationally. He is a key opinion leader in neuroblastoma and drug development in Europe and works for international networks such as SIOPEN (siopen.net) and ITCC (itcc-consortium.org). He leads the BEACON-Neuroblastoma trial open in 10 European countries for relapsed & refractory neuroblastoma. He has been principal investigator of more than 30 clinical trials and has co-authored more than 60 international publications in the field. He provides second opinion consultations for children and adolescents with relapsed/refractory cancers nationally and internationally to facilitate access to early clinical trials and novel agents. He is a keen supporter of incorporating the patient/parents voice into research and clinical practice and has started several projects on quality of life, quality of care, late effects and patient reported outcomes. His favourite conference of the year is the Solving Kids’ Cancer Parent conference because of the excellent interaction between researchers, clinicians and parents.
Proyectos Grup de Recerca Emergent (GRE) Childood Cancer & Blood disorders IP: Lucas Moreno Martín-Retortillo Colaboradores: Luís Gros Subias, Raquel Andreu Vilarroig, Andrea Vilaplana Blanes, Pablo Velasco Puyó, Laura Murillo Sanjuán, Maria Isabel Benitez Carabante, Aroa Soriano Fernández, Guillem Pons Barcons, Jose Miguel Lizcano De Vega, Maria Cristina Díaz de Heredia Rubio, Maria Luz Uría Oficialdegui, Maria Jose Pérez García, Miguel Segura Ginard, M Mar Mañu Pereira, Lorena Valero Arrese, Thaïs Murciano Carrillo, Constantino Sábado Álvarez, Anna Llort Sales, Elisabet Megías Roda, Raquel Hladun Alvaro, Grup de Recerca Emergent (GRE) Childood Cancer & Blood disorders, Carlota Aguilera Ordoñez, Adria Molero Valenzuela, Júlia Sansa Girona, Gabriela Guillén Burrieza, Laura Alonso Garcia, Victoria Gutierrez Valle, Idoia Bolinaga Ayala, Josep Roma Castanyer, Sergio Espinosa Gil, Elena Andretta, Claire Diot, Amira Idrizovic Entidad financiadora: Agència Gestió Ajuts Universitaris i de Recerca Financiación: 60000 Referencia: 2021 SGR 00638 Duración: 01/01/2022 - 30/06/2025 Implementación de la Oncología de Precisión en Pacientes Adolescentes y Adultos Jóvenes con Cáncer IP: Lucas Moreno Martín-Retortillo Colaboradores: Judit Álvarez González, María Paula Pérez Albert Entidad financiadora: Instituto de Salud Carlos III Financiación: 65000 Referencia: CM22/00241 Duración: 01/01/2023 - 31/12/2024 A phase I trial of ABTL0812 in paediatric patients with advanced cancer including neuroblastoma IP: Lucas Moreno Martín-Retortillo Colaboradores: Cristina Gamez Cenzano, Aroa Soriano Fernández, Luis Riera Soler, Miguel Segura Ginard, Carlota Aguilera Ordoñez, Sergio Manresa Vera Entidad financiadora: Instituto de Salud Carlos III Financiación: 826760.77 Referencia: ICI21/00076 Duración: 01/01/2022 - 31/12/2025 Implementation and new biomarker development for Personalised Medicine for Childhood Cancers in Spain IP: Lucas Moreno Martín-Retortillo Colaboradores: Aroa Soriano Fernández, Marta Garrido Pontnou, Miguel Segura Ginard, Lorena Valero Arrese, Raquel Hladun Alvaro, Elena Antima Martinez Saez, Marta Sese Faustino, Gabriela Guillén Burrieza, Josep Roma Castanyer, Andrea Vilaplana Blanes, Sergio Manresa Vera, Margarita Ortega Blanco, María Rosario Pérez- Torres Lobato, Asbleidy Carolina Torres Barbosa Entidad financiadora: Instituto de Salud Carlos III Financiación: 369260 Referencia: PMP21/00073 Duración: 01/01/2022 - 31/12/2025 Paginación Primera página « Página anterior ‹ Página 1 Página actual 2 Página 3 Página 4 Siguiente página › Última página »
